Search for

    Search Results


    Chronic Fatigue Syndrome Patients Benefit from CoQ10

    Research has shown that patients diagnosed with chronic fatigue syndrome (CFS) have abnormally low levels of CoQ10 in plasma and muscle tissue. Research has also shown that supplementing with a well-formulated CoQ10 preparation improves CFS symptoms.

    Researchers have determined that a low CoQ10 level is also an independent predictor of chronic heart failure (CHF). Mortality due to CHF may explain previous reports that the mean age of CFS patients dying from CHF is 25 years younger than the age of those dying from CHF in the general population.

    About Chronic Fatigue Syndrome
    Chronic fatigue syndrome is a chronic condition characterized by a debilitating fatigue. The fatigue may be exacerbated by physical or mental exertion. Oddly enough, the fatigue in CFS patients is not alleviated by rest or relaxation. CFS patients also suffer from unexplained muscle pain and various immunological symptoms. The cause of CFS is still unknown.

    Low CoQ10 Levels in CFS Patients
    In 2009, Dr. Michael Maes and colleagues at the Maes Clinics in Antwerp, Belgium, measured the concentrations of CoQ10 in plasma in 58 patients diagnosed with chronic fatigue syndrome and in 22 normal healthy study participants.

    The researchers found that the plasma CoQ10 levels in the CFS patients were significantly lower than the CoQ10 levels in the normal healthy study participants. Nearly half (44%) of the CFS patients had plasma CoQ10 levels below the lowest individual plasma CoQ10 concentration in the group of healthy study participants.

    Moreover, in the CFS patients, the researchers saw a significant inverse association between plasma CoQ10 levels and the patients’ scores on the Chronic Fatigue Syndrome Rating Scale, which is a scale used to determine the severity of the disease.  Lower CoQ10 status was significantly associated with higher levels of fatigue.

    The CFS patients with very low plasma CoQ10 concentrations were also the patients who suffered the most from concentration and memory disturbances.

    CoQ10 Depletion Activates Inflammation
    Inflammation is a protective response of the body’s immune system to harmful pathogens and toxins. Socalled inflammasomes are components of the innate immune system and are responsible for activating inflammatory processes.

    Fibromyalgia research on CoQ10 depleted tissue levels has shown a definite association between CoQ10 deficiency, on one hand, and the activation of pro-inflammatory markers and increased serum levels of pro-inflammatory cytokines, on the other hand.

    Treatment of CFS with CoQ10
    In 2016, researchers in Barcelona, Spain, treated patients with chronic fatigue syndrome with a daily combination of 200 milligrams of CoQ10 and 20 milligrams of nicotinamide adenine dinucleotide (NADH) or matching placebo for eight weeks.

    The researchers used an oral ubiquinone/CoQ10 supplement in this randomized controlled study. The ubiquinone form of Coenzyme Q10 is the completely oxidized form, the most well-documented form, and the form most commonly sold commercially.

    The data from the study showed a significant reduction in maximum heart rate during a cycle ergometer test in the 8th week versus baseline cycle test heart rate for the study participants receiving the CoQ10 plus NADH treatment.

    Moreover, the data showed that the participants’ reports of fatigue were significantly reduced in the active treatment group as contrasted with the placebo group.
    The CoQ10 plus NADH supplementation was safe and well-tolerated.


    Castro-Marrero J, et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial. Clin Nutr. 2016;35(4):826-34.

    Maes M, et al. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 2009;30(4):470-6.

    Cordero MD, et al. NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q10. Antioxid Redox Signal. 2014;20(8):1169-80.